Catrin Plumpton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8479016/publications.pdf

Version: 2024-02-01

516710 501196 30 992 16 28 citations h-index g-index papers 31 31 31 1529 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Random Subspace Ensembles for fMRI Classification. IEEE Transactions on Medical Imaging, 2010, 29, 531-542.	8.9	191
2	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1375-1386.	13.7	104
3	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1363-1374.	13.7	93
4	PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health Technology Assessment, 2018, 22, 1-114.	2.8	82
5	Costâ€effectiveness of screening for <i><scp>HLA</scp>â€<scp>A</scp>*31:01</i> prior to initiation of carbamazepine in epilepsy. Epilepsia, 2015, 56, 556-563.	5.1	59
6	Predictors of Self-Reported Adherence to Antihypertensive Medicines: A Multinational, Cross-Sectional Survey. Value in Health, 2015, 18, 206-216.	0.3	58
7	Multiple imputation of multiple multi-item scales when a full imputation model is infeasible. BMC Research Notes, 2016, 9, 45.	1.4	47
8	The cancer care experiences of gay, lesbian and bisexual patients: A secondary analysis of data from the UK Cancer Patient Experience Survey. European Journal of Cancer Care, 2017, 26, e12670.	1.5	40
9	Naive random subspace ensemble with linear classifiers for real-time classification of fMRI data. Pattern Recognition, 2012, 45, 2101-2108.	8.1	36
10	Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches. Pharmacoeconomics, 2016, 34, 447-461.	3.3	30
11	Societal Preferences for Funding Orphan Drugs in the United Kingdom: An Application of Person Trade-Off and Discrete Choice Experiment Methods. Value in Health, 2018, 21, 538-546.	0.3	30
12	Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery. British Journal of Clinical Pharmacology, 2015, 80, 1149-1159.	2.4	28
13	Linear mixed models to handle missing at random data in trialâ€based economic evaluations. Health Economics (United Kingdom), 2022, 31, 1276-1287.	1.7	27
14	Attitudes towards epilepsy in the UK population: Results from a 2018 national survey. Seizure: the Journal of the British Epilepsy Association, 2019, 65, 12-19.	2.0	26
15	Costâ€Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation Framework. Clinical Pharmacology and Therapeutics, 2019, 105, 1429-1438.	4.7	25
16	Patientâ€Focused Drug Development Methods for Benefit–Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs. Clinical Pharmacology and Therapeutics, 2019, 105, 672-683.	4.7	20
17	Investigating preferences for support with life after stroke: a discrete choice experiment. BMC Health Services Research, 2014, 14, 63.	2.2	18
18	Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technology Assessment, 2019, 23, 1-140.	2.8	18

#	Article	IF	CITATIONS
19	Economic evaluation of a behavior-modifying intervention to enhance antiepileptic drug adherence. Epilepsy and Behavior, 2015, 45, 180-186.	1.7	12
20	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Health Technology Assessment, 2021, 25, 1-134.	2.8	11
21	Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria. Wiener Klinische Wochenschrift, 2015, 127, 379-384.	1.9	9
22	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). BMJ Open, 2020, 10, e040635.	1.9	6
23	Semi-supervised ensemble update strategies for on-line classification of fMRI data. Pattern Recognition Letters, 2014, 37, 172-177.	4.2	5
24	Cost-effectiveness of <i>HLA-B*15:02</i> screening in Malaysia. British Journal of Dermatology, 2017, 177, 904-905.	1.5	5
25	Cost-Effectiveness of Pediatric Central Venous Catheters in the UK: A Secondary Publication from the CATCH Clinical Trial. Frontiers in Pharmacology, 2017, 8, 644.	3.5	5
26	Rare disease prevention and treatment: the need for a level playing field. Pharmacogenomics, 2018, 19, 243-247.	1.3	3
27	Renal transplant patients' preference for the supply and delivery of immunosuppressants in Wales: a discrete choice experiment. BMC Nephrology, 2017, 18, 305.	1.8	2
28	New advice on switching antiepileptic drugs might be a false economy. BMJ, The, 2013, 347, f7471-f7471.	6.0	1
29	Supporting People With Type 2 Diabetes in the Effective Use of Their Medicine Through Mobile Health Technology Integrated With Clinical Care to Reduce Cardiovascular Risk: Protocol for an Effectiveness and Cost-effectiveness Randomized Controlled Trial. JMIR Research Protocols, 2022, 11, e32918.	1.0	1
30	Reply. Ophthalmology, 2019, 126, e24-e25.	5.2	0